September 12, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
pSivida reports $18.5 million yearly loss
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In the fourth fiscal quarter of 2017, pSivida reported a net loss of $6.1 million, or $0.16 per share, compared with a net loss of $6.4 million, or $0.19 per share, in 2016’s fourth quarter.
Revenue for the quarter was reported at $701,000 compared with $304,000 in the fourth quarter of 2016, according to a press release.
The company reported $7.5 million in revenue for the full fiscal year, which ended June 30, 2017, compared with $1.6 million in 2016’s fiscal year. The increase was attributed to $5.6 million of revenue recognized upon termination of an agreement with Pfizer.
Net loss for the year was $18.5 million, or $0.52 per share, compared with a net loss of $21.5 million, or $0.68 per share, in the fiscal year ended June 30, 2016.